ArticleAdvances in radiation oncology
An analysis of prognostic factors associated with recurrence in the treatment of atypical meningiomas.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis.Neurosurgical review · 2023Pooled it
- Extent of resection and survival outcomes in World Health Organization grade II meningiomas.Journal of neuro-oncology · 2021Trial
- A machine learning-based integrated clinical model for predicting prognosis in atypical meningioma patients.Acta neurochirurgica · 2023Article
- NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.Journal of neuro-oncology · 2023Article
- DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study.Frontiers in oncology · 2022Article
- Combining FORGE Score and Histopathological Diagnostic Criteria of Atypical Meningioma Enables Risk Stratification of Tumor Progression.Diagnostics (Basel, Switzerland) · 2021Article
- Differentially Expressed MicroRNAs in Radioresistant and Radiosensitive Atypical Meningioma: A Clinical Study in Chinese Patients.Frontiers in oncology · 2020Article
- A Quantified Risk-Scoring System for the Recurrence of Meningiomas: Results From a Retrospective Study of 392 Patients.Frontiers in oncology · 2020Article
- A Novel Scoring System Based on Preoperative Routine Blood Test in Predicting Prognosis of Atypical Meningioma.Frontiers in oncology · 2020Article
- Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma.Radiation oncology (London, England) · 2019Article
- Prognostic factors of microsurgical treatment of intracranial meningiomas - A multivariate analysis.PloS one · 2018Article
- Predictor factors for recurrence in atypical meningiomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
- Tumor recurrence in parasagittal and falcine atypical meningiomas invading the superior sagittal sinus.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere has been increased reporting of atypical meningioma (grade II) since the World Health Organization reclassification in 2000, and the use of postoperative radiation therapy (RT) in the treatment of these tumors is controversial. We evaluated patients treated at our institution to identify patient subgroups with increased risk of recurrence that may benefit from adjuvant RT. METHODS AND MATERIALS: We retrospectively assessed 50 patients treated for World Health Organization grade II meningiomas between March 2000 and February 2013. Sex, race, age of diagnosis, tumor location, performance status, size of tumor, MIB-1 index, resection status, and RT were recorded. Patient follow-up, recurrence, and vital status were measured to assess 3-year overall survival (OS) and recurrence free survival (RFS).
resultsThe median follow-up was 37 months (range, 1-148). Female sex was associated with decreased RFS compared with male sex (86.1% vs 100%,
conclusionsSignificantly higher rates of recurrence occurred in female sex, subtotal resection, and tumors larger than 4.5 cm. Further studies are needed to confirm these findings and determine whether patients without any of these risk factors can undergo surgical resection without adjuvant radiation therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.